Immunogenicity of two‐dose sinopharm BBIB‐CorV vaccine in Morocco: One‐year follow‐up and neutralizing activity against severe acute respiratory syndrome coronavirus 2 variants of concern

Abstract Background This study aimed to evaluate the immunogenicity of a two‐dose Sinopharm BBIB‐CorV (Vero cells) vaccine against SARS‐CoV‐2, at 28 days, 6 months, and 1‐year postvaccination. And assess the capacity of two‐dose vaccine recipients to neutralize SARS‐CoV‐2 strains B.1 (Wuhan/D614G),...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maha Ouarab, Elarbi Bouaiti, Zineb Rhazzar, Hicham El Annaz, Safae el kochri, Mouhssine Hemlali, Hamza Ghammaz, Omar Nyabi, Karim el Bakkouri, Nadia Touil, Mostafa Elouennass, Lamiae Belayachi, Jean Luc Gala, Khalid Ennibi, Elmostafa El Fahime
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2024-11-01
Edice:	Immunity, Inflammation and Disease
Témata:	BBIBP‐CorV Sinopharm immunogenicity microneutralization assay neutralizing antibodies SARS‐CoV‐2
On-line přístup:	https://doi.org/10.1002/iid3.1359
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!